Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07570823 | A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 3 | 101 | Sinocelltech Ltd.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07678229 | BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL(BRIDGE-NK) | recruiting | Phase 3 | 150 | Rong TaoOTHER | 1 | Aug 13, 2026 |
| clinicaltrials |
| NCT07727083 | Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases(EBV-T/NK Cohor) | recruiting | — | 1,500 | Rong TaoOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07763054 | Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients | recruiting | — | 30 | Haikou Affiliated Hospital of Central South University Xiangya School of MedicineOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02595255 | AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)(CHANCE) | recruiting | — | 275 | Erasme University HospitalOTHER | 2 | Aug 12, 2026 | clinicaltrials |
| NCT03680677 | Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies | recruiting | — | 20 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04307576 | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | recruiting | Phase 3 | 6,430 | Mats HeymanOTHER | 15 | Aug 12, 2026 | clinicaltrials |
| NCT04707300 | Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO)(HTLP-ONCO) | recruiting | Phase 1 / Phase 2 | 10 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05188170 | Niclosamide in Pediatric Patients With Relapsed and Refractory AML | recruiting | Phase 1 | 16 | Stanford UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05444348 | Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)(ACT) | recruiting | N/A | 920 | Christoffer JohansenOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06323044 | MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence | recruiting | N/A | 150 | Roswell Park Cancer InstituteOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06340737 | AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | recruiting | Phase 1 | 148 | Stanford UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06792825 | HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL | recruiting | Phase 2 | 65 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07053059 | Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL) | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07280013 | A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | recruiting | Phase 1 | 60 | C4 Therapeutics, Inc.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07311746 | Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia | recruiting | Phase 1 / Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07513129 | Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma | recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07566364 | Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD | recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07754890 | Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 65 | Peking Union Medical College HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03081910 | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen(MAGENTA) | recruiting | Phase 1 | 54 | Baylor College of MedicineOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04708054 | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | recruiting | Phase 2 / Phase 3 | 324 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06159491 | Pacritinib in CMML | recruiting | Phase 1 / Phase 2 | 26 | Douglas TremblayOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06849713 | Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL | recruiting | Phase 2 | 80 | Massachusetts General HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07191249 | Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma .(SUNFLOW) | recruiting | Phase 2 | 40 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07342478 | ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL | recruiting | Phase 3 | 306 | Newave Pharmaceutical IncINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07486713 | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies | recruiting | Phase 4 | 16 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07603479 | JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 14 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03136146 | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia | recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05022446 | The Impact of COVID-19 on Pulmonary Procedures | recruiting | — | 250 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05108519 | Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies | recruiting | — | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05308264 | Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | recruiting | Phase 1 / Phase 2 | 86 | Rigel PharmaceuticalsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05389293 | A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma | recruiting | Phase 2 | 152 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05887167 | Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies | recruiting | Phase 1 | 20 | Joshua Sasine, MD, PhDOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05976555 | Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma | recruiting | Phase 1 | 30 | Medical College of WisconsinOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06105554 | Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06207799 | Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06285890 | Phase I Study of HC-7366 for Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06361641 | Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes(PHEMOP) | recruiting | N/A | 70 | University Hospital, AngersOTHER_GOV | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06390319 | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) | recruiting | Phase 2 | 100 | St. Jude Children's Research HospitalOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06529250 | Intermediate-dose HAD Regimen for CEBPA Double-mutated AML(HADCEBPA2023) | recruiting | N/A | 148 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06607549 | Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)(SOLAR) | recruiting | Phase 1 | 12 | University of UtahOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06823167 | A Phase 1 Study of IM-1021 in Participants With Advanced Cancer | recruiting | Phase 1 | 190 | Immunome, Inc.INDUSTRY | 4 | Aug 10, 2026 | clinicaltrials |
| NCT07131059 | MRD-positive AML Clinical Study | recruiting | N/A | 537 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07451054 | CD45BE-HSPC + CART-45 Cells | recruiting | Phase 1 | 42 | University of PennsylvaniaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07495631 | Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia | recruiting | N/A | 43 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07665307 | Delayed Toxicities Post-CAR-T | recruiting | — | 30 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07756034 | Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer(ONCO-OLIVIA) | recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 13, 2026source: clinicaltrials